Vishal Vaidya

Vishal Vaidya has over 17 years of experience in the biotechnology and pharmaceutical industry. In 2016, they began working at Pfizer as the Senior Director, Head of Clinical Biomarker Technologies. In this role, they were responsible for managing the clinical biomarker technology laboratories and executing biomarker science strategies for the clinical portfolio across all therapeutic areas. Vishal then moved to the role of Director, Translational Omics Laboratory Lead, where they built an effective team to deliver a direct portfolio and business impact for Rare Diseases, Oncology, Inflammation/Immunology and Internal Medicine portfolio. Vishal also led complex innovative projects with industry-academia teams of scientists. Finally, they were the Director, Biomarker Analytics Global Lead, where they provided high quality robust biomarker datasets from small and large animal studies as well as Phase 1 & 2 trials. In 2019, Vishal co-founded Mediar Therapeutics, a preclinical stage biotechnology company focused on developing therapeutics to target myofibroblast activation in fibrosis impacting liver, lung and kidney. Prior to this, Vishal worked at Harvard Medical School from 2003, where they were an Associate Professor, Assistant Professor, Instructor and Postdoctoral Fellow. Vishal led a diverse team of scientists and maintained consistent funding from NIH, industry, foundations and government. Their lab has won over 25 national awards/fellowships and their trainees are now employed in academia, industry and government.

Vishal Vaidya received their Bachelor of Pharmacy (BPharm) from Poona College of Pharmacy in 1998. Vishal then went on to pursue a Doctor of Philosophy (Ph.D.) in Pharmaceutical Sciences from the University of Louisiana Monroe, which they completed in 2003.